Catalent has entered an agreement to acquire a clinical packaging facility in Minakuchi, Japan, from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan. The acquisition establishes a new clinical GMP manufacturing and distribution hub to support clinical studies. Financial terms were not disclosed.
 
The 60,000-sq.-ft. facility will be the largest in the company’s Asia Pacific clinical supply network and will offer Catalent’s FastChain demand-led supply services, primary and secondary packaging capabilities, a range of temperature options for storage and distribution, as well as clinical returns and destruction services. It will operate in partnership with Catalent’s existing Japanese clinical supply facility at Kakegawa, serving both local and global pharma/biopharma companies.
 
“This new facility provides much-needed capacity as we look to expand our capabilities across the Asia-Pacific region, and follows on from recent expansions and investments we have made in our clinical supply business in China and Singapore,” said Ricci Whitlow, President, Catalent Clinical Supply Services. “Our strategy has been to build expertise and capacity in this region as demand for local clinical supply services increases, to provide support to customers with global programs, and to meet the growing demand in biologics and cell and gene therapy studies.”